PDSB
Live chart
What they do
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102.
For information only · Important disclosures
Grades vs sector
No sector grades for PDSB yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | -0.13 | -0.18 | -42.1% |
| 2026-05-13 | -0.14 | -0.13 | +7.1% |
| 2026-03-30 | -0.20 | -0.14 | +30.0% |
| 2025-11-13 | -0.20 | -0.19 | +3.4% |
| 2025-08-13 | -0.23 | -0.21 | +10.0% |
| 2025-05-14 | -0.25 | -0.21 | +14.9% |
| 2025-03-27 | -0.28 | -0.21 | +23.6% |
| 2024-11-14 | -0.28 | -0.29 | -2.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Analyst actions
PT $5
PT $7
PT $7
PT $15
PT $3
PT $15
Stats refreshed 2026-10-21 11:26:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026